Treatment pattern of systemic therapies in patients with metastatic melanoma and BRAF mutation test.

被引：0
|
作者：
Fu, Alex Z.
Li, Zhiyi
Tang, Jackson
Grzegorzewski, Kris
Mahmood, Syed
Whisman, Tyler
Quadri, Syed
Qiu, Ying
机构：
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Asclepius Analyt LLC, Brooklyn, NY USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e21003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21003
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status
    Nathan, P.
    Sharma, A.
    Lorigan, P.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1712 - 1713
  • [2] Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?
    Cybulska-Stopa, Bozena
    Czarnecka, Anna Malgorzata
    Ostaszewski, Krzysztof
    Piejko, Karolina
    Zietek, Marcin
    Dziura, Robert
    Rutkowska, Ewa
    Galus, Lukasz
    Calik, Jacek
    Salek-Zan, Agata
    Zemelka, Tomasz
    Kamycka, Agnieszka
    Bal, Wieslaw
    Kubiatowski, Tomasz
    Rogala, Pawel
    Switaj, Tomasz
    Kaminska-Winciorek, Grazyna
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Real world treatment patterns of first-line combination therapies among patients with metastatic melanoma and BRAF mutation.
    Qiu, Ying
    Li, Zhiyi
    Tang, Jackson
    Atanasov, Pavel
    Mahmood, Syed
    Grzegorzewski, Kris
    Chen, Lei
    Chen, Joyce S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] SURGERY, RADIATION, AND SYSTEMIC THERAPIES IN PATIENTS WITH METASTATIC MELANOMA
    Wang, S.
    Zhao, Z.
    Barber, B.
    Wagner, V
    VALUE IN HEALTH, 2012, 15 (04) : A232 - A233
  • [5] Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
    Czarnecka, Anna M.
    Teterycz, Pawel
    Mariuk-Jarema, Anna
    Lugowska, Iwona
    Rogala, Pawel
    Dudzisz-Sledz, Monika
    Switaj, Tomasz
    Rutkowski, Piotr
    TARGETED ONCOLOGY, 2019, 14 (06) : 729 - 742
  • [6] Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
    Anna M. Czarnecka
    Paweł Teterycz
    Anna Mariuk-Jarema
    Iwona Lugowska
    Pawel Rogala
    Monika Dudzisz-Sledz
    Tomasz Switaj
    Piotr Rutkowski
    Targeted Oncology, 2019, 14 : 729 - 742
  • [7] The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice
    Czarnecka, A. M.
    Teterycz, P.
    Lugowska, I.
    Rogala, P.
    Switaj, T.
    Rutkowski, P. L.
    ANNALS OF ONCOLOGY, 2018, 29 : 451 - 451
  • [8] Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma
    Gummadi, Tulasi
    Dronca, Roxana Stefania
    Kim, Chul
    Kottschade, Lisa A.
    Mittapalli, Rajendar K.
    Elmquist, William F.
    Dudek, Arkadiusz
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] BRAF-Mutation detection in metastatic Melanoma
    Dietel, M.
    Enk, A.
    Lehmann, A.
    Bauer, J.
    Garbe, C.
    Kellner, U.
    Kirchner, T.
    Jung, A.
    Kreipe, H.
    Merkelbach-Bruse, S.
    Buettner, R.
    Rueschoff, J.
    Schlake, W.
    Schirmacher, P.
    Penzel, R.
    Stadler, R.
    PATHOLOGE, 2012, 33 (04): : 352 - 356
  • [10] Analysis of BRAF mutation in primary and metastatic melanoma
    Libra, M
    Malaponte, G
    Navolanic, PM
    Gangemi, P
    Bevelacqua, V
    Proietti, L
    Bruni, B
    Stivala, F
    Mazzarino, MC
    Travali, S
    McCubrey, JA
    CELL CYCLE, 2005, 4 (10) : 1382 - 1384
12345